XNASXOMAO
Market cap305mUSD
Dec 24, Last price
25.60USD
1D
0.16%
1Q
-0.27%
Name
XOMA Corp
Profile
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 4,758 -21.06% | 6,027 -84.21% | 38,160 29.86% | |||||||
Cost of revenue | 26,646 | 23,441 | 20,802 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (21,888) | (17,414) | 17,358 | |||||||
NOPBT Margin | 45.49% | |||||||||
Operating Taxes | (15) | 91 | ||||||||
Tax Rate | 0.52% | |||||||||
NOPAT | (21,888) | (17,399) | 17,267 | |||||||
Net income | (40,831) 138.72% | (17,104) -208.27% | 15,798 18.80% | |||||||
Dividends | (5,472) | (5,472) | (3,499) | |||||||
Dividend yield | 1.88% | 1.93% | 1.38% | |||||||
Proceeds from repurchase of equity | (148) | 1,021 | 37,711 | |||||||
BB yield | 0.05% | -0.36% | -14.83% | |||||||
Debt | ||||||||||
Debt current | 5,651 | 34 | 195 | |||||||
Long-term debt | 119,242 | 68 | 263 | |||||||
Deferred revenue | 7,228 | 9,550 | 11,685 | |||||||
Other long-term liabilities | (34) | 11,685 | ||||||||
Net debt | (28,558) | (121,742) | (162,719) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (18,158) | (12,879) | 22,678 | |||||||
CAPEX | (17) | (23,247) | (26,500) | |||||||
Cash from investing activities | (711) | (20,221) | (26,500) | |||||||
Cash from financing activities | 120,593 | (4,451) | 12,835 | |||||||
FCF | (24,109) | (17,222) | 17,434 | |||||||
Balance | ||||||||||
Cash | 153,451 | 58,161 | 94,102 | |||||||
Long term investments | 63,683 | 69,075 | ||||||||
Excess cash | 153,213 | 121,543 | 161,269 | |||||||
Stockholders' equity | (1,223,088) | (1,182,257) | (1,165,154) | |||||||
Invested Capital | 1,443,541 | 1,315,855 | 1,330,538 | |||||||
ROIC | 1.31% | |||||||||
ROCE | 11.29% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 11,471 | 11,413 | 12,192 | |||||||
Price | 25.41 2.45% | 24.80 18.95% | 20.85 -16.57% | |||||||
Market cap | 291,479 2.97% | 283,065 11.35% | 254,203 -11.57% | |||||||
EV | 262,970 | 161,372 | 91,533 | |||||||
EBITDA | (20,988) | (17,310) | 17,365 | |||||||
EV/EBITDA | 5.27 | |||||||||
Interest | 569 | 295 | 461 | |||||||
Interest/NOPBT | 2.66% |